Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. More Details
Flawless balance sheet and good value.
Share Price & News
How has Coral Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 524506 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 524506's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 524506 exceeded the Indian Pharmaceuticals industry which returned 47.6% over the past year.
Return vs Market: 524506 exceeded the Indian Market which returned 7.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Coral Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 years ago | Simply Wall StIs Coral Laboratories Limited's (BOM:524506) 10.70% ROE Strong Compared To Its Industry?
2 years ago | Simply Wall StBest Growth Stocks To Buy Now
2 years ago | Simply Wall StFlavor Of The Month: I G Petrochemicals And More
Is Coral Laboratories undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 524506 (₹310.95) is trading below our estimate of fair value (₹344.61)
Significantly Below Fair Value: 524506 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 524506 is good value based on its PE Ratio (8.6x) compared to the IN Pharmaceuticals industry average (21.2x).
PE vs Market: 524506 is good value based on its PE Ratio (8.6x) compared to the Indian market (17.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 524506's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 524506 is good value based on its PB Ratio (0.9x) compared to the IN Pharmaceuticals industry average (2.2x).
How is Coral Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Coral Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Coral Laboratories is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Coral Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Coral Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524506 has high quality earnings.
Growing Profit Margin: 524506's current net profit margins (16%) are higher than last year (4.6%).
Past Earnings Growth Analysis
Earnings Trend: 524506's earnings have declined by 10.1% per year over the past 5 years.
Accelerating Growth: 524506's earnings growth over the past year (289.3%) exceeds its 5-year average (-10.1% per year).
Earnings vs Industry: 524506 earnings growth over the past year (289.3%) exceeded the Pharmaceuticals industry 24.6%.
Return on Equity
High ROE: 524506's Return on Equity (9.9%) is considered low.
How is Coral Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: 524506's short term assets (₹1.0B) exceed its short term liabilities (₹231.6M).
Long Term Liabilities: 524506's short term assets (₹1.0B) exceed its long term liabilities (₹32.5M).
Debt to Equity History and Analysis
Debt Level: 524506's debt to equity ratio (1.5%) is considered satisfactory.
Reducing Debt: 524506's debt to equity ratio has reduced from 4.6% to 1.5% over the past 5 years.
Debt Coverage: 524506's debt is well covered by operating cash flow (434.2%).
Interest Coverage: 524506 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Coral Laboratories's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 524506's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 524506's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 524506's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 524506's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 524506 is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 524506's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Girish Dhameja (39 yo)
Mr. Girish Madanlal Dhameja has been an Whole-Time Director of Coral Laboratories Limited since May 26, 2017. His present profile includes handling export enquiry finalization and execution of order, busin...
CEO Compensation Analysis
Compensation vs Market: Girish's total compensation ($USD28.24K) is below average for companies of similar size in the Indian market ($USD49.89K).
Compensation vs Earnings: Girish's compensation has been consistent with company performance over the past year.
|Whole-Time Director||no data||₹2.09m||no data|
|CFO & Non-Executive Director||3.5yrs||₹1.26m||no data|
|Non-Executive Independent Director||6.17yrs||₹43.00k||no data|
|Non-Executive Independent Director||3.5yrs||₹40.00k||no data|
|Additional Non-Executive Director||1.5yrs||no data||no data|
|Additional Independent Director||1.5yrs||₹15.00k||no data|
Experienced Board: 524506's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Coral Laboratories Limited's company bio, employee growth, exchange listings and data sources
- Name: Coral Laboratories Limited
- Ticker: 524506
- Exchange: BSE
- Founded: 1994
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹1.111b
- Shares outstanding: 3.57m
- Website: https://corallab.com
Number of Employees
- Coral Laboratories Limited
- #3B, Patanwala Industrial Estate
- Opp. Shreyas Cinema
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|524506||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Aug 1998|
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethopia, and internationally. The company offers antibiotics/antibacterial products, including antifungal, antiemetic...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/29 12:16|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.